Aquestive Therapeutics, Inc.AQSTEarnings & Financial Report
Nasdaq
NextMar 31, 2026
AQST Q3 2025 Key Financial Metrics
Revenue
$12.8M
Gross Profit
$8.3M
Operating Profit
$-11.5M
Net Profit
$-15.4M
Gross Margin
64.8%
Operating Margin
-89.6%
Net Margin
-120.6%
YoY Growth
-5.4%
EPS
$-0.14
Financial Flow
Aquestive Therapeutics, Inc. Q3 2025 Financial Summary
Aquestive Therapeutics, Inc. reported revenue of $12.8M for Q3 2025, with a net profit of $-15.4M (-120.6% margin). Cost of goods sold was $4.5M, operating expenses totaled $19.8M.
Key Financial Metrics
| Total Revenue | $12.8M |
|---|---|
| Net Profit | $-15.4M |
| Gross Margin | 64.8% |
| Operating Margin | -89.6% |
| Report Period | Q3 2025 |
Aquestive Therapeutics, Inc. Annual Revenue by Year
Aquestive Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $57.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $57.6M |
| 2023 | $50.6M |
| 2022 | $47.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $12.1M | $20.1M | $13.5M | $11.9M | $8.7M | $10.0M | $12.8M |
| YoY Growth | 23.6% | 8.3% | 51.8% | 4.2% | -10.1% | -27.7% | -50.2% | -5.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $57.4M | $129.5M | $117.6M | $110.0M | $101.4M | $102.2M | $93.7M | $163.6M |
| Liabilities | $163.9M | $165.8M | $153.1M | $155.4M | $161.6M | $163.2M | $166.3M | $167.7M |
| Equity | $-106.5M | $-36.3M | $-35.5M | $-45.4M | $-60.2M | $-60.9M | $-72.6M | $-4.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.9M | $-10.4M | $-7.0M | $-11.9M | $-6.5M | $-23.4M | $-7.9M | $-12.6M |